8-KThe WireStrategic
Material Agreement
Filed Mar 5, 2026 · 4mo ago · Accession 0001193125-26-092654
Plain English
Tenaya Therapeutics, Inc. entered into a collaboration agreement with Alnylam Pharmaceuticals, Inc. to discover and validate gene targets for cardiovascular disease. Alnylam will have exclusive rights to develop products from validated targets and may pay up to $1.13 billion in milestones.
Filing details
- Company
- Tenaya Therapeutics, Inc.
- Ticker
- TNYA
- CIK
- 1858848
- Form type
- 8-K
- Filing date
- Mar 5, 2026
- Report date
- Mar 4, 2026
- Document
- tnya-20260304.htm
- Size
- 162 KB